In re Neurontin Antitrust Litigation, Nos. 02-1830, 02-2731 and 02-5583; U.S. District Court; opinion by Hochberg, U.S.D.J.; filed August 27, 2009. DDS No. 59-7-5248 [54 pp.]
Defendants Warner-Lambert Company and Pfizer Inc. have marketed gabapentin under the tradename Neurontin since 1994. They initially obtained two patents, the ’175 and ’544 patents, in connection with gabapentin. Their Neurontin products were developed on the basis of these patents. They obtained new drug applications (NDAs) 235 and 882 for the use of gabapentin to treat epilepsy.
